Investigating the role of specific tumor suppressors in bladder cancer
Official title: BLR&D Research Career Scientist Award Application
Funded at VA Medical Center · NIH-10948926 · Data updated 2026-11-12
This study is looking at how the loss of a specific gene called CDKN2B might help cause low-grade bladder cancer, and it's for anyone interested in understanding this type of cancer better so we can find new ways to diagnose and treat it.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Medical Center NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | October 1, 2018 |
| Project end | September 30, 2030 |
| Funding year | 2025 |
| NIH project number | 5IK6BX004479-07 |
| Project ID | NIH-10948926 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include veterans and individuals at risk for bladder cancer, particularly those with a family history or genetic predispositions.
✕Less likely to help
Patients with advanced bladder cancer or those who do not have the specific genetic markers being studied may not benefit from this research.
What this research studies
This research focuses on understanding how the loss of certain tumor suppressors, particularly CDKN2B, contributes to the development of low-grade, non-invasive bladder cancer. The study utilizes various methodologies, including genetic analysis of bladder tumor cell lines and engineered mice, as well as human specimen evaluations, to explore the mechanisms behind tumor initiation and progression. By redefining the role of CDKN2B, the research aims to uncover new insights that could lead to improved diagnostic and therapeutic strategies for bladder cancer. The project also emphasizes mentoring future researchers and fostering collaborations within the urological community.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnoses and targeted treatments for bladder cancer, ultimately improving patient outcomes.
How similar studies have gone: Previous research has shown promising results in understanding the genetic factors involved in bladder cancer, indicating that this approach has potential for significant advancements.
Where this research is happening
-
VA Medical Center
New York, United States Active
Researchers
- Principal investigator: Wu, Xue-Ru — VA Medical Center
- Study coordinator: Wu, Xue-Ru
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.